Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in CVS Health Corporation $CVS

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in CVS Health Corporation (NYSE:CVS) by 5.7% in the 4th quarter, HoldingsChannel reports. The fund owned 2,662,759 shares of the pharmacy operator’s stock after acquiring an additional 144,166 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in CVS Health were worth $213,367,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Alteri Wealth LLC grew its holdings in CVS Health by 3.2% in the 3rd quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock valued at $316,000 after buying an additional 131 shares during the period. TOWER TRUST & INVESTMENT Co boosted its position in shares of CVS Health by 0.8% in the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after acquiring an additional 132 shares during the last quarter. Holistic Financial Partners grew its holdings in CVS Health by 4.1% in the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock valued at $256,000 after purchasing an additional 133 shares during the period. CYBER HORNET ETFs LLC increased its position in CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after purchasing an additional 134 shares during the last quarter. Finally, LS Investment Advisors LLC raised its stake in CVS Health by 3.9% during the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after purchasing an additional 135 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Trading Up 7.7%

NYSE CVS opened at $86.89 on Thursday. The company’s fifty day moving average price is $76.60 and its two-hundred day moving average price is $78.00. The company has a market capitalization of $111.35 billion, a price-to-earnings ratio of 62.96, a price-to-earnings-growth ratio of 0.84 and a beta of 0.60. CVS Health Corporation has a 12 month low of $58.35 and a 12 month high of $88.63. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter last year, the company posted $2.25 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts predict that CVS Health Corporation will post 7.14 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s payout ratio is presently 192.75%.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Leerink Partners restated an “outperform” rating and set a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. Piper Sandler lowered their price target on CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a research report on Tuesday, March 31st. The Goldman Sachs Group lifted their price objective on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Bank of America decreased their target price on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a report on Tuesday, January 27th. Finally, Robert W. Baird boosted their price objective on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $94.61.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q1 beat and guidance raise — CVS reported adjusted EPS $2.57 vs. $2.21 expected, revenue $100.4B vs. ~$95B expected, and raised FY2026 adjusted EPS guidance to $7.30–7.50 (above street). Management cited improved medical cost controls at Aetna and stronger pharmacy/benefits performance, which explains the rally. PR Newswire: CVS first-quarter results
• Positive Sentiment: Improved insurance margins — Aetna reported a materially lower medical benefit ratio (~84.6% vs. 87.3% year-ago), helping margins and cash-flow outlook, a key driver of the upside in the stock. Reuters: CVS raises 2026 forecast
• Positive Sentiment: Cost control via formulary changes — CVS Caremark will prefer interchangeable biosimilars over some branded drugs (effective July 1), which should lower drug spend for clients and help pharmacy margins over time. PR Newswire: CVS Caremark biosimilar adoption
• Neutral Sentiment: Analyst and market context — HSBC nudged its price target slightly higher to $85 (hold), a modest validation but not a major catalyst. Macro beats (private payrolls) and calmer geopolitical headlines helped broader market sentiment. MarketScreener: HSBC raises PT Zacks: Private payrolls up
• Negative Sentiment: Formulary changes could trigger pushback — preferring biosimilars and dropping J&J’s Stelara from main formularies may prompt manufacturer, provider or political pushback and legal scrutiny, which could create noise or revenue disruption in specific categories. Reuters: CVS drops Stelara

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.